Data as of Apr 17
| +2.48 / +8.84%|
Prothena Corp. Plc is a biotechnology company, focuses on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion. It also focuses on the discovery and development of potential therapeutic monoclonal antibodies directed specifically to disease causing proteins. These potential therapies have a broad range of indications including AL and AA forms of amyloidosis, Parkinson's disease and related synucleinopathies, and novel cell adhesion targets involved in inflammatory disease and metastatic cancers. The company was founded on September 26, 2012 and is headquartered in Dublin, Ireland.
|Dale B. Schenk||President, Chief Executive Officer & Director|
|Tran B. Nguyen||Chief Financial Officer & Head-Investor Relations|
|Gene G. Kinney||Chief Scientific Officer & Head-Research|
|Martin Koller||Chief Medical Officer|
|Karin L. Walker||Chief Accounting Officer & Controller|